Why the study?
Does chemotherapy improve survival and response rates in adults with soft tissue sarcomas?
Population
Adults with soft tissue sarcomas, including those with inoperable disease or metastases, and in the adjuvant…
Design
Review
Authors
Loading...
Supports doxorubicin as first-line; confirms modest adjuvant benefit yet leaves optimal regimens open.
Does chemotherapy improve survival and response rates in adults with soft tissue sarcomas?
Single-agent doxorubicin remains the standard first-line chemotherapy for advanced adult soft tissue sarcomas, while adjuvant chemotherapy offers a small survival benefit.
O’Byrne et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: